Revisiting evidence of blood pressure-dependent and independent effects of amlodipine on the risk of stroke

Journal of Clinical Hypertension

Volumn 13, Issue 10, 2011, Pages 781-782

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE;

BLOOD PRESSURE; DRUG MECHANISM; FOLLOW UP; LETTER; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE;

EID: 80053566388     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00485.x     Document Type: Letter

References (10)

1. Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175, 634 patients. J Hypertens. 2009;27:1136-1151.
2. Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50:181-188.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997 Erratum in: JAMA. 2004;291:2196. JAMA 2003;289:178.
4. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BP Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
5. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal BP: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
6. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
9. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51:393-398.
10. Deeks JJ, Higgins JP, Altman DG, eds. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Accessed March 1, 2011.